Calcium channel antagonists. What do the second-generation agents have to offer?
Calcium channel antagonists have gained widespread acceptance for treatment of a variety of cardiovascular disorders. Newer drugs of the dihydropyridine class are especially attractive for treating hypertension and angina because of their increased vascular selectivity, favorable side-effect profile, and pharmacokinetics that allow once-daily dosing. In the future, calcium channel antagonists may also play a role in antiatherogenic therapy and in treatment of congestive heart failure and cerebrovascular disease as results of prospective studies become available and new agents are developed.
Salerno
S M
SM
Madigan Army Medical Center, Tacoma, Washington.
Zugibe
F T
FT
D001161:Arteriosclerosis / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D004095:Dihydropyridines / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D014700:Verapamil; D004110:Diltiazem